Avalo Therapeutics (AVTX)
Develops an anti-IL-1β antibody for immune-mediated inflammatory diseases.
$19.35
Pre-market−0.01 (−0.05%)
At close$19.36(+2.16%)
Something off on this page? Send us feedback.
Next report
Nov 5, 2026
estimated · in 63 days
EPS estimate
−$0.56
Revenue estimate
—
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Apr '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$7.95−$1.25−$1.92−$2.19−$0.37−$0.98−$0.83Pending
Estimate$0.58−$1.07−$1.43−$1.67−$1.54−$1.00−$0.58−$0.56
Surprise−1,470.7%−16.8%−34.3%−31.1%+76.0%+2.0%−42.4%—
RevenueReportedEstimate
Apr '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$192.0K———$79.5K——Pending
Estimate————$59.0K———
Surprise————+34.7%———
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.56 | — | — |
| Aug 2026 | −$0.58 | −$0.83 | −42.4% |
| May 2026 | −$1.00 | −$0.98 | +2.0% |
| Mar 2026 | −$1.54 | −$0.37 | +76.0% |
| Nov 2025 | −$1.67 | −$2.19 | −31.1% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Apr 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| Jul 2024 | |||
| May 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Mar 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Mar 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Apr 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Mar 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Mar 2016 | |||
| Nov 2015 | |||
| Jun 2015 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Nov 5, 2026 | −$0.56 | — | — | — | — | — | — |
| Aug 6, 2026 | −$0.58 | −$0.83 | −42.4% | — | — | — | −0.7% |
| May 13, 2026 | −$1.00 | −$0.98 | +2.0% | — | — | — | −4.2% |
| Mar 23, 2026 | −$1.54 | −$0.37 | +76.0% | $59.0K | $79.5K | +34.7% | −0.4% |
| Nov 6, 2025 | −$1.67 | −$2.19 | −31.1% | — | — | — | −2.4% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||||||
| Aug 7, 2025 | |||||||
| May 12, 2025 | |||||||
| Apr 4, 2025 | |||||||
| Nov 7, 2024 | |||||||
| Aug 12, 2024 | |||||||
| Jul 11, 2024 | |||||||
| May 13, 2024 | |||||||
| Nov 9, 2023 | |||||||
| Aug 3, 2023 | |||||||
| May 4, 2023 | |||||||
| Mar 29, 2023 | |||||||
| Nov 7, 2022 | |||||||
| Aug 4, 2022 | |||||||
| May 5, 2022 | |||||||
| Mar 2, 2022 | |||||||
| Nov 9, 2021 | |||||||
| Aug 2, 2021 | |||||||
| May 13, 2021 | |||||||
| Mar 8, 2021 | |||||||
| Nov 9, 2020 | |||||||
| Aug 6, 2020 | |||||||
| May 7, 2020 | |||||||
| Mar 11, 2020 | |||||||
| Nov 14, 2019 | |||||||
| Aug 8, 2019 | |||||||
| May 9, 2019 | |||||||
| Mar 18, 2019 | |||||||
| Nov 13, 2018 | |||||||
| Aug 9, 2018 | |||||||
| May 11, 2018 | |||||||
| Apr 2, 2018 | |||||||
| Nov 6, 2017 | |||||||
| Aug 14, 2017 | |||||||
| May 9, 2017 | |||||||
| Mar 14, 2017 | |||||||
| Nov 8, 2016 | |||||||
| Aug 15, 2016 | |||||||
| May 16, 2016 | |||||||
| Mar 23, 2016 | |||||||
| Nov 13, 2015 | |||||||
| Jun 30, 2015 | |||||||